What does CD19 CAR-T cell therapy involve?

This therapy begins with collecting your own T cells via apheresis. These cells are genetically modified in a lab to express a chimeric antigen receptor (CAR) targeting CD19 on B-cell lymphoma cells. After a short course of lymphodepleting chemotherapy, the CAR-T cells are infused back into your bloodstream. They then multiply and attack the cancer cells. The entire inpatient process typically takes 3–4 weeks, with close monitoring for side effects.